GleamWall
中文EN

PBH Prestige Consumer Healthcare Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1295947 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.1%
TTM net income YoY-22.8%
TTM EPS YoY-19.8%
Revenue 3-yr CAGR1.2%
Net income 3-yr CAGR—

Margins

Gross margin52.5%
Operating margin25.0%
Net margin13.3%
FCF margin18.4%
EBITDA margin28.1%

Returns

ROE8.2%
ROA3.8%
ROIC (approx.)6.9%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets58.8%
Debt / equity1.07x
Current ratio2.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.48x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q22026-09-302027Q12026-06-302026Q4*2026-03-312026Q32025-12-312026Q22025-09-302026Q12025-06-302025Q4*2025-03-312025Q32024-12-31
Income statement
Revenue$336.31M$265.71M$281.62M$283.44M$274.11M$249.53M$296.52M$290.32M
Cost of revenue$163.77M$129.52M$135.32M$126.08M$122.53M$109.20M$126.51M$129.27M
Gross profit$172.54M$136.19M$146.30M$157.37M$151.58M$140.33M$170.01M$161.05M
SG&A expense$30.89M$43.30M$30.28M$29.67M$28.04M$28.46M$27.05M$26.18M
Operating income$80.71M$52.52M$75.49M$82.49M$79.67M$71.76M$88.43M$91.96M
Interest expense——————-$35.07M$11.46M
Income tax$22.16M$9.36M$10.84M$15.12M$26.92M$14.31M$23.83M$19.12M
Net income$25.30M$29.18M$53.93M$46.70M$42.21M$47.47M$50.13M$61.03M
EBITDA$92.68M$61.27M$83.84M$90.08M$87.33M$79.42M$95.68M$98.83M
EPS (basic)0.530.61—0.980.860.96—1.23
EPS (diluted)0.530.61—0.970.860.95—1.22
Weighted avg. shares (diluted)47.59M47.60M—48.09M49.26M49.83M—49.99M
Banking
Net interest income-$30.03M—-$11.43M-$10.67M-$10.04M-$10.20M-$10.76M-$11.46M
Provision for credit losses——$0———$0—
Balance sheet
Cash & equivalents$46.52M$89.13M$63.87M$62.37M$119.11M$139.50M$97.88M$50.87M
Receivables$244.12M$187.35M$191.92M$190.46M$199.00M$168.41M$194.29M$167.27M
Inventory$179.20M$190.22M$159.13M$163.59M$159.00M$153.13M$147.71M$151.52M
Current assets$492.13M$496.81M$431.48M$433.43M$497.41M$480.52M$448.33M$377.16M
PP&E, net$116.87M$117.18M$121.69M$128.21M$73.10M$73.79M$74.55M$73.52M
Goodwill$705.26M$650.79M$581.11M$581.25M$528.41M$528.31M$527.42M$527.22M
Intangibles$3.36B$3.24B$2.30B$2.30B$2.29B$2.29B$2.30B$2.31B
Total assets$4.72B$4.57B$3.49B$3.49B$3.44B$3.43B$3.40B$3.33B
Current liabilities$168.50M$153.81M$120.92M$139.56M$134.60M$109.67M$106.62M$102.55M
Short-term debt—$10.45M$0—————
Long-term debt$2.08B$2.01B$993.95M$1.03B$993.15M$992.75M$992.36M$1.00B
Total debt$2.08B$2.02B$993.95M$1.03B$993.15M$992.75M$992.36M$1.00B
Total liabilities$2.78B$2.65B$1.61B$1.67B$1.62B$1.58B$1.57B$1.54B
Shareholders' equity$1.94B$1.92B$1.89B$1.83B$1.82B$1.86B$1.83B$1.79B
Net debt$2.03B$1.93B$930.09M$971.17M$874.04M$853.25M$894.47M$949.13M
Cash flow statement
Operating cash flow$37.87M$70.79M$42.84M$78.29M$57.49M$79.01M$61.85M$65.09M
Capital expenditure$3.62M$3.70M$5.21M$3.03M$2.10M$838,000$3.48M$1.57M
Free cash flow$34.24M$67.08M$37.63M$75.26M$55.38M$78.17M$58.37M$63.52M
Investing cash flow-$138.90M-$1.06B-$3.41M-$128.56M-$2.93M-$1.94M-$3.48M-$9.82M
Financing cash flow$58.30M$1.02B-$38.10M-$6.73M-$74.95M-$36.28M-$11.49M-$53.87M
Depreciation & amortization$11.96M$8.75M$8.35M$7.59M$7.66M$7.67M$7.25M$6.87M
Stock-based compensation$1.23M$3.99M$2.65M$2.74M$1.77M$3.68M$2.73M$2.87M
Share buybacks$0$0$690,000$45.82M$75.00M$34.77M$11.31M$2.40M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.